Teijin (3401) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
2 Oct, 2026Executive summary
First-half revenue rose ¥35.3B YoY to ¥507.5B, and adjusted operating income increased ¥7.2B to ¥18.6B.
Net loss attributable to owners of parent was ¥53.4B; a ¥57.8B impairment, mainly on North American composites assets, drove operating income to -¥47.7B.
IFRS was adopted from FY2024, with adjusted operating income used as a key metric and prior periods restated for comparison.
FY2024 guidance targets ¥25B profit, ¥28B adjusted operating income and a ¥50 annual dividend; guidance reflects the INFOCOM sale gain and composites impairment.
Financial highlights
First-half revenue was ¥507.5B (+7.5% YoY), adjusted operating income ¥18.6B (+62.7%), and EBITDA ¥55.6B (+11.8%).
Gross profit declined to ¥78.6B from ¥108.1B; operating income fell to -¥47.7B from ¥1.8B, reflecting impairment losses.
Net loss per share was ¥277.06, compared with ¥10.17 in the prior-year period.
Cash and cash equivalents were ¥110.1B at period end, down from ¥123.2B at March 31, 2024; free cash flow was -¥7.5B.
Operating cash flow was ¥23.2B, investing cash flow -¥30.7B and financing cash flow ¥34.7B.
Outlook and guidance
FY2024 revenue forecast is ¥1,010B (+5.2% YoY); adjusted operating income is ¥28B, up ¥6B YoY and ¥5B versus prior guidance.
Profit attributable to owners of parent is forecast at ¥25B, with basic EPS of ¥129.78; the forecast includes a ¥101.5B INFOCOM sale gain.
Annual dividend forecast rose to ¥50 per share from ¥30; FY2024 ROE is forecast at 6%.
Full-year free cash flow is projected at ¥140B, with D/E expected to improve to 1.0.
FY2024 EBITDA is forecast at ¥100B, with CAPEX of ¥70B and R&D expenses of ¥31B.
Latest events from Teijin
- Profit and AOI surged on asset sales, with higher outlook and ongoing segment reorganization.3401
Q1 2027 - Aiming for customer-driven growth, profitability, and strong ESG performance by FY2028.3401
Investor presentation - FY2026 targets profit recovery and growth amid restructuring and stable dividends.3401
Q4 2026 - Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 2026 - Protect PC earnings while scaling non-PC growth, high-value products and circular materials.3401
Investor Day 2025 - Q1 revenue and adjusted income declined; FY2025 guidance and the ¥50 dividend remain unchanged.3401
Q1 2026 - Focus on home healthcare, rare diseases, and innovation drives long-term growth.3401
Investor Update - Q1 earnings rebounded, FY2024 guidance rose and the planned Infocom sale advanced.3401
Q1 2025